Primary ovarian insufficiency secondary to chemotherapy with inotuzumab ozogamicin and other agents

Recent advances in targeted therapy with monoclonal antibodies have significantly improved outcomes for people with cancer, sometimes allowing patients to avoid ovotoxic agents altogether. The current understanding is that monoclonal antibody cancer therapies that are not targeted to ovarian antigen...

Descripción completa

Detalles Bibliográficos
Autores principales: Maristany, Sumiko, DuVall, Adam S., Stock, Wendy, Adeleye, Amanda J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Fertility Preservation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9209836/
https://www.ncbi.nlm.nih.gov/pubmed/35727422
http://dx.doi.org/10.1007/s10815-022-02548-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9209836/
https://www.ncbi.nlm.nih.gov/pubmed/35727422
http://dx.doi.org/10.1007/s10815-022-02548-3

Ejemplares similares